Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended				12 Months Ended		24 Months Ended	30 Months Ended
	Jul. 31, 2022	Jan. 31, 2021	Dec. 31, 2019	Jun. 30, 2019	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2021	Nov. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue					$ 38,627	$ 29,750
Deferred revenue, current					37,633	41,212	$ 41,212	$ 41,212
Gilead Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment				$ 45,000
Upfront payment of additional fees				$ 3,000
Research milestones payments received								34,500
Variable consideration included in transaction price					$ 34,500
Collaboration agreement contract term (in years)					5 years
Collaboration revenue					$ 23,700	16,600
Collaboration revenue recognized from opening contract liability					18,400	11,100
Performance obligation satisfied					4,000	3,100
Recorded deferred revenue					27,400	41,100	41,100	41,100
Deferred revenue, current					18,200	19,900	19,900	19,900
Accounts receivable						6,000	6,000	6,000
Gilead Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total additional payments receivable					2,300,000
Development milestone payments, receivable					667,500
Sales milestone payments, receivable					1,500,000
Additional fees receivable related to target licensing, reservation and selection and research term extensions					136,800
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment			$ 55,000		55,000
Research milestones payments received							3,000
Variable consideration included in transaction price					4,000
Collaboration revenue					15,000
Collaboration revenue recognized from opening contract liability					14,000	13,000
Performance obligation satisfied					600	100
Recorded deferred revenue					46,200	59,200	59,200	59,200
Deferred revenue, current					19,400	21,300	$ 21,300	$ 21,300
Additional payment received to exercise option to expand number of targets		$ 22,000
Payment received to exercise option to expand number of targets		$ 22,000
Collaborative agreement expected transaction price					77,000
Collaborative agreement additional transaction price					22,000
Additional variable consideration included in transaction price					$ 1,000
Contractual initial research period (in years)	5 years 3 months				4 years 3 months
Revenue from contract with a customer						$ 13,200
Contract assets					$ 1,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments, receivable					496,000
Sales milestone payments, receivable					1,300,000
Milestone payments additional fees, total					2,500,000
Regulatory milestone payments, receivable					625,000
Additional fees receivable related to target licensing and reservation					$ 126,500